$1.52
▼ -0.7% Today
as of Jul 22, 16:52 ET
Last 30 days
Recent Press Releases & News
NanoViricides Seeks Approval for Phase 2 Trial of NV-387 Oral Gummies to Treat Ebola in Congo
As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola
NanoViricides Says Phase 2 Trial of NV-387 for Ebola Receives Ethics Approval in Congo
Overview
52-week range
$0.85
$2.23
49% of range
Avg surprise (last 0)
—
Avg reaction (last 2)
+2.6%
100% positive
Latest IV / EM
532%
EM ±121.7% · $3 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 14, 2026 | Mar/2026 | $-0.09 | — | — | +35.7% | +1.2% | earnings |
| Wed Dec 31, 2025 | Dec 2025 | $-0.11 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $-0.10 | — | — | — | — | financials |
| Thu May 15, 2025 | Mar/2025 | $-0.14 | — | — | — | +4.0% | earnings |
| Tue Dec 31, 2024 | Dec 2024 | $-0.14 | — | — | — | — | financials |
| Mon Sep 30, 2024 | Sep 2024 | $-0.23 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.16 | — | — | — | — | financials |
| Sun Dec 31, 2023 | Dec 2023 | $-0.18 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.17 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | — | — | — | $0 | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-2M | $-2M | $-2M | — | $-2M | $-2M | $-3M | — |
| Net income | $-2M | $-2M | $-2M | — | $-2M | $-2M | $-3M | — |
| EPS (diluted) | $-0.09 | $-0.11 | $-0.10 | — | $-0.14 | $-0.14 | $-0.23 | — |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $3M | $5M | $1M | $2M | $3M | $4M | $4M | $5M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $3M | $5M | $1M | $2M | $3M | $4M | $4M | $5M |
| Total assets | $10M | $12M | $8M | $9M | $10M | $12M | $12M | $13M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $1M | $1M | $1M | — | — | $1M | $2M | — |
| Total equity | $9M | $11M | $7M | $8M | $9M | $10M | $10M | $11M |